Literature DB >> 30194768

Disparities in Postoperative Therapy for Salivary Gland Adenoid Cystic Carcinomas.

Richard J Cassidy1, Jeffrey M Switchenko2, Mark W El-Deiry3, Ryan H Belcher3, Jim Zhong1, Conor E Steuer4, Nabil F Saba4, Mark W McDonald1, David S Yu1, Theresa W Gillespie5, Jonathan J Beitler1,3,4.   

Abstract

OBJECTIVES: The patterns of care for salivary gland adenoid cystic carcinomas (ACC) are unknown. We sought to assess predictors of receiving postoperative radiation and/or chemotherapy for patients with nonmetastatic, definitively resected ACC, as well as report unexpected nodal disease.
METHODS: The National Cancer Data Base was queried for definitively resected nonmetastatic ACC from 2004 to 2014. Logistic regression, Kaplan-Meier, and Cox proportional-hazard models were utilized. Propensity-score matched analysis was employed to reduce confounding variables.
RESULTS: A total of 3,136 patients met entry criteria: 2,252 (71.8%) received postoperative radiation, with 223 (7.4%) also receiving concurrent chemotherapy. Median follow-up was 4.87 years. In clinically lymph node negative (cN0) patients, 7.4% had pathologically positive lymph nodes (pN) + after elective neck dissection. Patients who lived closer to their treatment facility and had positive margins were more likely to receive postoperative radiation. Black patients and uninsured patients were less likely to receive radiation. Older age, male sex, advancing stage, and positive surgical margins were associated with worse overall survival (OS). With limited follow-up, receipt of radiation or chemotherapy was not associated with OS.
CONCLUSION: Postoperative radiation was frequently given for resected ACC, with a minority receiving chemotherapy. Black patients and uninsured patients were less likely to receive radiation. Postoperative radiation and/or chemotherapy had no association with OS but were given in greater frequency in more advanced disease, and our series is limited by short follow-up. The disparity findings for this rare disease need to be addressed in future studies. LEVEL OF EVIDENCE: 2c Laryngoscope, 129:377-386, 2019.
© 2018 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Adenoid cystic carcinoma; National Cancer Data Base; healthcare disparities; postoperative chemotherapy; postoperative radiation; salivary gland tumors

Mesh:

Year:  2018        PMID: 30194768      PMCID: PMC6344280          DOI: 10.1002/lary.27302

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  31 in total

1.  A comparison of the demographics, clinical features, and survival of patients with adenoid cystic carcinoma of major and minor salivary glands versus less common sites within the Surveillance, Epidemiology, and End Results registry.

Authors:  Nan Li; Li Xu; Hui Zhao; Adel K El-Naggar; Erich M Sturgis
Journal:  Cancer       Date:  2011-12-16       Impact factor: 6.860

2.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.

Authors:  R A Deyo; D C Cherkin; M A Ciol
Journal:  J Clin Epidemiol       Date:  1992-06       Impact factor: 6.437

3.  A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study.

Authors:  Peter C Austin; Paul Grootendorst; Geoffrey M Anderson
Journal:  Stat Med       Date:  2007-02-20       Impact factor: 2.373

4.  Adenoid cystic carcinoma of salivary origin. A clinicopathologic study of 242 cases.

Authors:  R H Spiro; A G Huvos; E W Strong
Journal:  Am J Surg       Date:  1974-10       Impact factor: 2.565

5.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

6.  Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501).

Authors:  Jacques Bernier; Jay S Cooper; T F Pajak; M van Glabbeke; J Bourhis; Arlene Forastiere; Esat Mahmut Ozsahin; John R Jacobs; J Jassem; Kie-Kian Ang; J L Lefèbvre
Journal:  Head Neck       Date:  2005-10       Impact factor: 3.147

Review 7.  Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review.

Authors:  Scott A Laurie; Alan L Ho; Matthew G Fury; Eric Sherman; David G Pfister
Journal:  Lancet Oncol       Date:  2010-12-10       Impact factor: 41.316

8.  Adenoid cystic carcinoma of the head and neck.

Authors:  Christopher J Balamucki; Robert J Amdur; John W Werning; Mikhail Vaysberg; Christopher G Morris; Jessica M Kirwan; William M Mendenhall
Journal:  Am J Otolaryngol       Date:  2012-01-04       Impact factor: 1.808

9.  Patterns of recurrence and survival of head and neck adenoid cystic carcinoma after definitive resection.

Authors:  Agnes Oplatek; Enver Ozer; Amit Agrawal; Sumit Bapna; David E Schuller
Journal:  Laryngoscope       Date:  2010-01       Impact factor: 3.325

10.  Prognostic factors affecting the clinical outcome of adenoid cystic carcinoma of the head and neck.

Authors:  Yoon Ho Ko; Myung Ah Lee; Yeong Seon Hong; Kyung Shik Lee; Chan-Kwon Jung; Yeon Sil Kim; Dong-Il Sun; Bum Soo Kim; Min Sik Kim; Jin Hyoung Kang
Journal:  Jpn J Clin Oncol       Date:  2007-11       Impact factor: 3.019

View more
  2 in total

1.  Analysis of postoperative radiotherapy for non-metastatic head and neck adenoid cystic carcinoma based on SEER data.

Authors:  Yan Du; Yong Zeng
Journal:  J Int Med Res       Date:  2022-08       Impact factor: 1.573

Review 2.  Occult Neck Metastases in Head and Neck Adenoid Cystic Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Jacopo Zocchi; Matteo Campa; Giulia Bianchi; Oreste Iocca; Pasquale Di Maio; Gerardo Petruzzi; Silvia Moretto; Flaminia Campo; Armando De Virgilio; Vincent Vander Poorten; Raul Pellini
Journal:  J Clin Med       Date:  2022-08-22       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.